Literature DB >> 14966821

Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.

Andrea von Berg1, Prakash M Jeena, Peter A Soemantri, André Vertruyen, Peter Schmidt, Fronke Gerken, Hassan Razzouk.   

Abstract

The objective of this study was to compare the efficacy and safety of ipratropium bromide/fenoterol hydrobromide (IB/FEN; Berodual) delivered from the novel propellant-free Respimat Soft Mist Inhaler (SMI) with that from a chlorofluorocarbon (CFC) metered-dose inhaler (MDI) plus spacer in children with asthma. The study followed a multicenter, randomized, double-blind (within Respimat SMI), parallel-group design. During the 2-week run-in period, patients received two actuations of CFC-MDI tid (IB 20 microg/FEN 50 microg per actuation) via a spacer (Aerochamber) (MDI 40/100). Patients (n=535) were then randomized to: Respimat SMI containing IB 10 microg/FEN 25 microg (Respimat SMI 10/25), IB 20 microg/FEN 50 microg (Respimat SMI 20/50), one actuation tid or CFC-MDI containing IB 20 microg/FEN 50 microg per actuation (in total 1B 40 microg/FEN 100 microg), or two actuations tid via Aerochamber (MDI 40/100), for 4 weeks. The primary endpoint was the change in forced expiratory volume in 1 second (FEV1) during the first 60 min after dosing (area under the curve from 0-1 h [AUC(0-1 h)]) on day 29. Analysis of the primary endpoint demonstrated that the efficacy of Respimat SMI 10/25 and 20/50 was equivalent to or greater than that of MDI 40/100. Similar results indicating that Respimat SMI 10/25 and 20/50 were not inferior to MDI 40/100 were also found on days 1 and 15. Analyses of other secondary endpoints supported these results. The safety profile of Respimat SMI was comparable to that of the CFC-MDI plus spacer. In conclusion, IB/FEN delivered via Respimat SMI is at least as effective as, and is as safe as, when delivered via CFC-MDI plus Aerochamber in children with asthma. Use of Respimat SMI thus enables a 2-4-fold reduction in the nominal dose of IB/FEN, and obviates the need for a spacer. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966821     DOI: 10.1002/ppul.10428

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  10 in total

Review 1.  Asthma outcomes: exacerbations.

Authors:  Anne Fuhlbrigge; David Peden; Andrea J Apter; Homer A Boushey; Carlos A Camargo; James Gern; Peter W Heymann; Fernando D Martinez; David Mauger; William G Teague; Carol Blaisdell
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

Review 2.  A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.

Authors:  Frank Kässner; Rick Hodder; Eric D Bateman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat((R)) Soft Misttrade mark Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma.

Authors:  Walter Vincken; Theo Bantje; Michelle V Middle; Fronke Gerken; Diane Moonen
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

4.  Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.

Authors:  Rick Hodder; Demetri Pavia; Angela Lee; Eric Bateman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-04-26

5.  A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old.

Authors:  Wolfgang Kamin; Marion Frank; Sabine Kattenbeck; Petra Moroni-Zentgraf; Herbert Wachtel; Stefan Zielen
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-04-06       Impact factor: 2.849

Review 6.  Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma.

Authors:  Francesca Santamaria; Carla Ziello; Paola Lorello; Cristina Bouchè; Melissa Borrelli
Journal:  Front Pediatr       Date:  2022-07-19       Impact factor: 3.569

7.  Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.

Authors:  Rick Hodder; Pat Ray Reese; Terra Slaton
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-06-11

Review 8.  Use of Respimat Soft Mist inhaler in COPD patients.

Authors:  Paula Anderson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

9.  Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders.

Authors:  Richard N Dalby; Joachim Eicher; Bernd Zierenberg
Journal:  Med Devices (Auckl)       Date:  2011-09-01

10.  Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.

Authors:  Peter Brand; Bettina Hederer; George Austen; Helen Dewberry; Thomas Meyer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.